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Introduction
The histone acetyltransferases (HATs) CBP and p300 are important coactivators favoring transcription. Their involvement in various pathological processes has been extensively studied in the past (1) . In fact, CBP and p300 are known as functional paralogues and their HAT domains show sequence identity of more than 90% (2) . Both proteins are fundamental coactivators of a large number of transcription factors by remodeling chromatin. Moreover, p300 and CBP can bind to target proteins and regulate DNA binding affinity, transcriptional activation, protein-protein interactions, and stability of transcription factors, but also other cellular proteins by acetylation (3) . For that reason, HATs are also named lysine acetyltransferases (KATs) (4) .
In cancer, the role of p300 and CBP is not clear and may depend on the physiological background of the tumor. The fact that p300 is targeted by viral oncoproteins and is often found mutated or in a truncated form in breast, colorectal, and pancreatic cancers, indicate that p300 may act as a classical tumor suppressor (5) . In prostate cancer, however, p300 and CBP clearly have oncogenic potential. Both p300 and CBP are coactivators of the androgen receptor (AR), the latter driving progression of prostate cancer by the regulating action of dihydrotestosterone (DHT) (6) . Acetylation of AR has been shown to enhance coactivator binding and promote prostate cancer cell growth (7) . Surgical or chemical androgen ablation is the first-line treatment of metastatic prostate cancer; however, after one to two years therapy eventually fails leading to the phenotype of castration-resistant prostate cancer. One of the mechanisms of castration resistance involves alterations in the balance between AR and its transcriptional coregulators (8) . In fact, in advanced prostate cancer p300 and CBP are highly expressed and androgen deprivation leads to an upregulation of both proteins (9, 10) .
Moreover, it was postulated that p300 could regulate androgen-dependent genes in the 6 absence or in the presence of very low levels of AR (11) . Interestingly, in several prostate cancer cell lines the agonistic action of the anti-androgen hydroxyflutamide was enhanced through CBP (12) . Likewise, p300 mediates androgen-independent transactivation of the AR by interleukin-6 (13), a cytokine which may facilitate prostate cancer progression through stimulation of proliferation and angiogenesis and inhibition of apoptosis (14) .
The p65 subunit of nuclear factor -țB (NF-țB) is a well-known target of p300 and CBP (15) .
NF-țB is a transcriptional factor, which is frequently constitutively activated in cancer (16) .
The prototypical NF-țB factor is a heterodimer of the p65 and p50 subunits belonging to the NF-țB/Rel family. NF-țB is sequestered and kept inactive in the cytoplasm by inhibitor of țB-Į (IțBĮ). Upon pathway activation by different extracellular stimuli NF-țB shuttles to the nucleus and transactivates hundreds of genes involved in different biological processes including inflammation, proliferation, and cell survival (17) . Besides their chromatin remodeling function on țB elements, p300 and CBP also acetylate p65 itself. Recently, it has been shown that the acetylation of lysine 310 of p65 impairs methylation of lysines 314 and 315, which is important for the ubiquitination and degradation of chromatin-associated p65 (18) .
A variety of histone deacetylase (HDAC) inhibitors have been developed in the last years. In fact, the U.S. Food and Drug Administration has licensed Vorinostat and Romidepsin for the treatment of cutaneous T-cell lymphoma. Several other HDAC inhibitors are currently being validated in clinical trials. Molecular mechanisms of HDAC inhibitors are induction of cellcycle arrest, differentiation, and tumor cell death. Induction of programmed cell death is mediated by intrinsic and extrinsic apoptosis pathways, generation of reactive oxygen species, inhibition of angiogenesis, and autophagy (19) . On the other hand, the use of HAT inhibitors as anti-cancer agents has received little attention, due to the lack of selective, potent, and cell (20) . Here we report on the potential use of p300/CBP inhibition in therapy of androgen-dependent and castration-resistant prostate cancer. To this end we selected two approaches: i) inhibiton of p300 or CBP via protein downregulation with specific siRNAs and ii) chemical inhibition of p300/CBP´s HAT/KAT activity with the above mentioned compound.
Materials and Methods

Cell culture and authentification, transfections, and treatments
All cell lines were cultured in RPMI containing 10% FCS and 1% antibiotics and glutamax.
LAPC-4 cells were supplemented with 100 nM DHT. Cell line authenticity was confirmed in August 2010 by short tandem repeat analysis following the procedure by Parson et al (21) .
Lipofectamine 2000 transfections were performed in serum-and antibiotics-free medium with 50 nM siRNA according to the manufacturer´s protocol (Invitrogen, Lofer, Austria).
Target sequence for p300 was published previously (13) , siControl and siCBP (On-target Plus Smart Pools) were purchased from Dharmacon (THP, Vienna, Austria). Six hours after transfection, medium was changed to full growth conditions. Cells were harvested 72 hours post-transfection. Since C646 was inhibited by serum (Fig. S1) , treatment with the chemical inhibitors was performed for 24 hours in serum-free HITES medium (RPMI medium supplemented with 10 nM hydrocortisone, 10 nM estradiol, 5 μg/ml insulin, 100 μg/ml transferrin, and 30 nM sodium selenite).
Western Blot
Western Blot was performed as described before (22) . For p300 and CBP 3-8% Tris/Acetate Gels and for p65, p50 and Bcl-xL 4-12% Bis/Tris Gels were used. Antibodies were purchased 
Proliferation assays
Cells were incubated for the last 16 hours with 37 kBq/well 3 H-thymidine and DNA was measured as described before (22) .
Apoptosis assays
Cells were seeded in 6-wells and transfected with siRNA or treated with C37 or C646 on the next day as described above. Cells were harvested and centrifuged. For flow cytometry cell pellets were resuspended in propidium iodide (PI) buffer (0.2% Triton-X-100, 2 ng/ml NaCitrate, and 0.1 mg/ml PI) and cell cycle distribution was measured with a FACS Calibur Cells were incubated in serum-free medium for the last 24 hours prior to harvesting. Prostatespecific antigen (PSA) concentration was determined on an Advia Centaur XP Immunoassay System (Siemens, Munich, Germany). Cells were trypsinized and counted with a Casy Counter (Schärfe System, Reutlingen, Germany). PSA concentrations were normalized to cell number.
Quantitative PCR
Quantitative PCR was performed as described before (22) . Taqman Primer/Probe mixes for p65, p50, Bcl-xL, and matrix metalloproteinase (MMP) -2 and -9 were purchased from Applied Biosystems (Vienna). Sybr Green Primers for p300 and CBP were published previously (23) .
Scratch (wound healing) and Boyden chamber assays
Scratch and Boyden chamber assays were performed as described before (24) . For invasion assays inserts were coated with Matrigel (Becton Dickinson) diluted 1:3 with serum-free medium.
Zymography
Cells were transfected as described above and after two days serum-free medium was added for the last 24 hours. Supernatant was collected and concentrated using Vivaspin 500 (VWR) to approximately 50 μl. Protein was quantified by the Bradford method and equal amounts of protein were loaded onto 10% Gelatin-Zymograms (Invitrogen). Gels were Coomassiestained and decolored until clear bands indicating proteinase activity were visible. 
Chromatin immunoprecipitation assays
Statistical analysis
Student´s t-test was used to assess significant differences between siControl or C37-treated groups and the indicated treated group (unless identified otherwise in the figure legend) and were encoded as follows: * p<0.05; ** p<0.01; *** p<0.001.
Results
Specific downregulation of p300 by siRNA reduces proliferation and induces apoptosis.
Inhibition of p300 and CBP was carried out by siRNA transfections and was confirmed to be efficient in the castration-resistant cell line PC3 and in the androgen-sensitive cell line LNCaP three days after transfection (Fig. 1a) . Quantitative PCR showed reduced mRNA levels of p300 and CBP at 24, 48, and 72 hours after transfection and confirmed specificity of siRNAs (Fig. S2) . To test whether inhibition of p300/CBP has anti-proliferative effects on prostate cancer cells, we measured 3 H-thymidine incorporation on transfected PC3 and LNCaP cells (Fig. 1b) . In PC3 depletion of both p300 and CBP resulted in a decreased proliferation, whereas LNCaP showed a significant decrease after p300 downregulation only. Moreover, decreased proliferation correlated with reduced PSA secretion in LNCaP cells, indicating a loss of transcriptional activity of the AR (Fig. 1c) . Decreased 3 H-thymidine incorporation can be a consequence of increased apoptosis. Therefore, we measured cell cycle distribution after staining the cells with PI (Fig. 1d) . Quantification of the sub-G 1 peak revealed that downregulation of p300 leads to an increase of apoptosis in both cell lines. Surprisingly, downregulation of CBP did not lead to an increase of apoptosis in either cell line. We concluded that expression of p300, but obviously not of CBP, is essential for the survival of PC3 and LNCaP cells.
Induction of apoptosis by p300 depletion involves both extrinsic and intrinsic pathways.
To determine whether induction of apoptosis by p300 depletion is a caspase-dependent mechanism, we measured activities of the extrinsic initiator caspases 8 and 10, the intrinsic initiator caspase 9, and the executioner caspases 3 and 7 (Fig. 2a) . Downregulation of p300 led to a 13.8-fold and 4.2-fold increase in caspase 3/7 activity in PC3 and LNCaP, respectively. Again, downregulation of CBP had no effect on caspase 3/7 activity. Moreover, both extrinsic and intrinsic apoptotic pathways were activated to the same extent after p300 depletion (Fig. 2a) . We confirmed the involvement of the extrinsic pathway by using specific inhibitors of caspases 8 and 9 (Fig. 2b) . Indeed, inhibition of the extrinsic pathway by caspase 8 inhibitor led to a significant reduction of caspase 3/7 activity after p300 depletion in both cell lines. Repression of the intrinsic pathway resulted only in a minor reduction of caspase 
3/7 activity. These findings show that apoptosis is induced primarily via the extrinsic pathway.
Downregulation of p300 induces p65 degradation.
Constitutive activation of NF-țB is a widely observed phenomenon in several cancer types including prostate cancer, as NF-țB regulates a variety of apoptotic antagonists (25) . We hypothesized that in the absence of p300 proper signaling of NF-țB is inhibited, thereby rendering the prostate cancer cells sensitive to apoptotic stimuli. We analyzed expression levels of the two main NF-țB subunits p65 (Rel A) and p50 after treatment with specific siRNAs for p300 and CBP. Indeed, in p300-depleted cells the protein level of p65 was decreased and this reduction was accompanied by the appearance of a higher molecular weighted band (Fig. 3a) . Moreover, mRNA levels of p65 were not affected significantly (Fig.   3a) , which led to the conclusion that p65´s degradation rate is probably increased after p300 downregulation. Analysis of p50 showed slight upregulation of protein levels in both p300-depleted PC3 and p300-or CBP-depleted LNCaP (Fig. 3b) , while p50 mRNA levels were not changed (Fig. 3b) . Taken together, these data indicate that upon p300 depletion NF-țB signaling is impaired through p65 degradation.
Inhibition of p300 decreases the invasive capacity of prostate cancer cells through a MMP-2 and -9 dependent mechanism.
The metastatic cascade is a well-regulated molecular process underlying different steps, including epithelial-mesenchymal transition, invasion, resistance to anoikis, angiogenesis, transport through vessels, and outgrowth of secondary tumors (26) . Due to p300/CBP´s interaction with a large number of pathways, we tested whether the two coactivators also interfere with metastatogenesis. Indeed, in scratch assays p300-or CBP-depleted PC3 cells showed impaired wound healing (Fig. 4a) . A reduced migration was confirmed after p300 or 
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CBP downregulation by measuring transition of PC3 and LNCaP cells through 8 μm pores of a PET membrane in Boyden chambers assays (Fig. 4b) . The same Boyden chambers were coated with matrigel and used to measure invasion (Fig. 4c) . Interestingly, only p300 depletion resulted in a significant reduction of invasiveness in both cell lines showing again that p300 and CBP can regulate different cellular processes. MMPs are enzymes that degrade among others collagen and gelatin thereby regulating the tumor microenvironment. It has been shown that MMP-2 and -9 are expressed in prostate cancer (27, 28) . Using gelatinzymography we measured the activity of MMP-9. PC3 cells showed a reduced protease activity after p300 depletion. This was corroborated with a reduced transcription of the MMP-9 gene (Fig. 4d) . The mRNA levels of MMP-2, a known activator of pro-MMP-9 (29), were also significantly decreased upon sip300 transfection. Interestingly, MMP-2 and -9 mRNA expressions in LNCaP were nearly undetectable (data not shown). Reduced invasion capacity of LNCaP cells was supported by a diminished number of cells undergoing migration, when comparing coated and uncoated Boyden chamber assays (Fig. 4b, c) . Taken together, we conclude that both CBP and p300 play a role in regulating motility of prostate cancer cells.
However, by regulating the expression of MMP-2 and -9, p300 appears to be most critical in impacting the molecular pathways of invasion.
The chemical p300 inhibitor C646 induces apoptosis in androgen-sensitive and castration-resistant prostate cancer cell lines by interfering with AR and NF-țB pathways.
To support our findings of reduced survival by inhibiting p300 with the siRNA approach, we tested whether chemical inhibition of p300 would also lead to these effects. The compound C646 specifically inhibits the acetyltransferase activities of p300 and CBP (20) , whereas C37 is an analog control compound that lacks acetyltransferase inhibitory properties (Fig. S3) . We and Du145, and two androgen-sensitive cell lines, LNCaP and LAPC-4. In caspase 3/7 activity assays, both PC3 and Du145 and in particular LNCaP showed an increase of apoptosis after treatment with 10 and 20 μM C646, but were insensitive to the control compound C37 (Fig. 5a) . Interestingly, LAPC-4 showed only a marginal increase of caspase 3/7 activity at the highest concentration. For this reason 20 μM C646 was used in subsequent experiments. Apoptosis induction was confirmed by Annexin-V staining of C646-treated cells (Fig. 5b) . Moreover, an induction of caspase 8/10 and caspase 9 activity after C646 treatment could be observed, showing again an involvement of both extrinsic and intrinsic pathways after inhibition of p300 (Fig. S4) . Next, we analyzed whether AR and NF-țB pathways were affected after treatment with C646. In LNCaP and LAPC-4 PSA secretion was markedly reduced after treatment with 20 μM C646 (Fig. 6a) . However, chromatin binding of AR was not affected by C646, suggesting that acetylation of AR is not a prerequisite for its DNA binding activity (Fig. S5) . Furthermore, decreased expression levels of p65 were observed in all cell lines (Fig. 6b) , which was associated with a decreased binding of p65 at the IțBĮ promoter (Fig. 6c) . Bcl-xL, an anti-apototic member of the Bcl-2 family, which is regulated by NF-țB, was also decreased in all cell lines except LAPC-4, giving a possible explanation for the low sensitivity of LAPC-4 to apoptotic induction by C646 (Fig. 6b) . Moreover, both MMP-2 and -9 mRNA expressions were significantly decreased in PC3 cells, showing that C646 may also interfere with cell invasion (Fig. 6d) . Altogether, these results show that chemical inhibition of p300/CBP´s HAT/KAT function is leading to induction of apoptosis via distinct molecular pathways. In the cellular processes of induction of apoptosis and invasion we found differential functions of p300 and CBP by using specific siRNAs. In the past, differential properties of p300 and CBP have been found in various cellular pathways. For example, Kawasaki and colleagues found that p300, but not CBP is needed for retinoic acid-induced differentiation of embryonal carcinoma F9 cells, whereas both proteins were required for the induction of apoptosis and G 1 -arrest (30) . Furthermore, multilineage defects in hematopoietic differentiation were found in mice with a monoallelic inactivation of the CBP gene. However, these pathologies could not be observed in p300 heterozygous mice, suggesting that a full complement of CBP, but not p300 is required for normal hematopoietic differentiation (31) .
For more examples on differential roles of p300 and CBP we refer to an interesting review by Kalkhoven (1) . Recently, a genome-wide ChIP-Seq has been performed on cell cyclesynchronized cells with specific antibodies against p300 or CBP (32). Interestingly, significant differences in the levels and binding targets of both proteins were observed.
Among processes differentially regulated by p300/CBP binding were also cell death and cell adhesion pathways. Taken together, those studies support our findings of differential effects of p300 and CBP.
Induction of apoptosis by p300 inhibition through multiple pathways.
Since it is known that p300 and CBP interfere with multiple pathways, we considered that induction of apoptosis is not restricted to one pathway. The AR is of particular importance in LNCaP and LAPC-4 cells that will stop growing after androgen depletion (33, 34) .
Knockdown of p300 decreased PSA secretion, which is an indicator of diminished AR activity. AR-regulated transcription may be impaired due to the lack of p300 as an important coactivator of AR. Furthermore, during prostate cancer progression from androgendependence to castration resistance, crosstalk between transduction pathways plays an important role in the ligand-independent activation of the AR (8) . shown that IL-6 activation of AR-dependent genes in the absence of androgens is mediated by p300 (13) . Thus, a combined treatment of AR blockade (e.g. bicalutamide) for liganddependent and p300 inhibition for ligand-dependent and -independent activation of the AR could be of potential interest.
In the second pathway, we found that p300 depletion leads to a decreased p65 level, apparently through increased turnover of the protein. This is in line with the results of a previous study, where deacetylation of lysine 310 of p65 led to Set9-mediated methylation of p65 at lysines 314 and 315, which, in turn resulted in polyubiquitination and proteasomal degradation of chromatin-associated p65 (18). Although we were not able to identify the nature of the higher molecular weighted band recognized by the p65 antibody in Fig. 3a , it seems to be linked to the absence of p300 rather than to the inhibition of p300´s acetyltransferase activity, since it was not observable after treatment with C646. Constitutive activation of NF-țB can be found in many prostate cancer cell lines and frequently correlates with AR downregulation (35) . It was proposed that NF-țB may compensate for the lack of androgen-induced AR activity by activating the expression of several AR target genes (35) .
Indeed, this possibility was demonstrated in LNCaP cells, where NF-țB activated the expression of PSA (36) . Thus, compromised NF-țB signaling can confer a decrease in NF-țB-and AR-responsive genes, resulting in a lack of activated pro-survival pathways and rendering prostate cancer cells susceptible to apoptotic induction. Interestingly, degradation of p65 after p300 downregulation could also be seen in LNCaP cells that do not show constitutively activated NF-țB signaling (37) . This correlated also with a lower apoptotic rate when comparing LNCaP to PC3 cells (Figs. 1d, 2a) . Thus, p65 downregulation might be less important in LNCaP cell growth effects. 
The involvement of the extrinsic pathway in induction of apoptosis after p300 inhibition was demonstrated by the use of caspase 8/10 activity assays and inhibitors of caspase 8 and/or 9. It is well known that the activation of the extrinsic pathway turns on the intrinsic pathway by the action of Bid (38) , while transactivation of the extrinsic by the intrinsic pathway has not been demonstrated. Therefore, high caspase 9 activity could be induced by crosstalk with the extrinsic pathway. On the other hand, we have also found deregulation in the AR-and NF-țB-signaling pathways leading to a lack of pro-proliferative stimuli. Hence, deregulation of intracellular pathways sensitizes cells to apoptosis induction. We therefore hypothesize that both intrinsic and extrinsic pathways contribute to programmed cell death after p300 inhibition. Interestingly, HDAC inhibitors also activate both apoptotic pathways (19) , although it seems that in this case the intrinsic one has a superior role over the extrinsic pathway.
Decrease of invasion by p300 inhibition.
Inhibition of tumor cell dissemination is of particular interest in prostate cancer, since most patients die from metastatic lesions, rather than from the primary tumor. In addition to the pro-apoptotic effect of p300 inhibition, we have found a decrease in cell migration and invasion. In fact, this reduction in migration and invasion is certainly also due to the increase of apoptotic cells. However, since we have found that p300 inhibition decreases expression of MMP-2 and 9, we conclude that p300 also interferes, as a distinct event, with the cellular pathways that regulate invasion. Interestingly, CBP depletion also led to a decrease in migration, but not invasion in either cell line. Thus, we concluded that both p300 and CBP are important for the regulation of migration, while only p300 is essential for invasion. Moreover, MMP-2 and -9 are known targets of NF-țB regulation (39) . It has been shown that MMP-9 is downregulated in PC3 cells that have been modified to have low NF-țB activity by the introduction of a mutant form of IțBĮ (40) . Hence, the decrease of p65 after p300 inhibition 18 may lead to lower NF-țB activity and MMP-9 expression. Vice versa, the high activity of NF-țB in untreated PC3 cells can explain the elevated expression of MMP-9, whereas in LNCaP cells, that have low NF-țB activity, MMP-2 and -9 were only faintly expressed. Since p300 inhibition could still decrease LNCaP invasion, we deduce that p300 also regulates other pathways important for invasion.
Potential of chemical p300 inhibition.
In addition to downregulation of p300/CBP by specific siRNAs we have used the small molecule C646, which has been shown to specifically inhibit the HAT/KAT domain of p300 and CBP (20) . C646 is a competitive inhibitor with a K i of 400 nM and is the most potent p300/CBP inhibitor in live cells (20) . We could observe similar effects of C646 on caspase activity, PSA secretion, and p65 expression levels compared to cells transfected with p300
siRNA. This led to the conclusion that apoptosis induction is dependent on the inhibition of p300´s HAT/KAT function. Moreover, the four examined cell lines showed varying sensitivity to C646, which leads to the conclusion that C646´s effects might be cell type-, time-and dose-dependent. Several other p300/CBP HAT inhibitors are known, e.g. the phytoextract curcumin (41) . Indeed, it has been shown that curcumin is able to induce apoptosis and to potentiate TNF-Į-induced apoptosis and suppress NF-țB activation in 
